Skip to content
OpenCapital
Get started

Arcutis Biotherapeutics, Inc. ARQT SG&A

SG&A at other companies

Pfizer logo
PfizerPFE
$2.96B-2.3%
Amgen logo
AmgenAMGN
$1.6B-5.0%
Incyte logo
IncyteINCY
$328.09M+0.7%
Organon logo
OrganonOGN
$424M+1.0%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$61.15M+40.5%
LQD
Liquidia CorporationLQDA
$46.94M+56.1%

Segments

By segment

See full
Reportable Segment$73.95M+15.8%

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.28B+57.5%
Enterprise value$3.36B+57.0%
P/S7.9×-1.9×

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s SG&A?
Arcutis Biotherapeutics, Inc. (ARQT) reported SG&A of $74.08M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s SG&A changed year-over-year?
Arcutis Biotherapeutics, Inc.'s SG&A increased by 15.7% year-over-year, from $64M to $74.08M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s SG&A?
Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s SG&A has grown at a 31.0% compound annual growth rate (CAGR), from $122.12M to $274.55M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.